Patent and Innovation Trends in GLP-1 and Weight Loss Drugs (20202025): What the IP and Science Signal Next This article was powered by Cypris Q, an AI agent that helps R&D teams instantly synthesize insights from patents, scientific literature, and market intelligence from around the globe
Asia-Pacific Asia-Pacific captured 19% share of the Liraglutide and Semaglutide market in 2024 and is projected to be the fastest-growing region during the forecast period
UK considerations NHS and MHRA guidance The UK health authorities have clear positions on weight loss treatments: The NHS offers GLP-1 medications through specialist weight management services for eligible patients MHRA has approved Wegovy, Saxenda, and Mounjaro based on comprehensive safety and efficacy data No GLP-1 patch products have received MHRA approval as weight loss treatments The MHRA has issued warnings about misleading claims in weight loss supplements Cost and access in the UK The financial aspect is a significant consideration for many: NHS provision : Limited availability through specialist weight management services with strict eligibility criteria Private prescriptions : 150-300 monthly, depending on medication and provider Commercial patches : 12-70 monthly, depending on brand and quantity While patches appear less expensive, they lack evidence of effectiveness, making them poor value regardless of price
Evidence and recommendations for imaging liver fat in children, based on systematic review
We note that without information on peoples BMI and underlying medical risk factors, it is not possible to determine whether this reflects a genuine medical need
To offer insight into the latest trends about these medications, Truveta Research has created the GLP-1 RA monitoring report, which will be updated periodically with fresh, timely data
00967-0/asset/1cda1e69-507e-47d1-ad73-620bcd1cbb66/main.assets/gr2_lrg.jpg)
